Evidence map›Paper›PMID 28371468›Full record

ArticleCNS neuroscience & therapeutics2017

Tremorolytic effect of 5'-chloro-5'-deoxy-(±)-ENBA, a potent and selective adenosine A1 receptor agonist, evaluated in the harmaline-induced model in rats.

Barbara Kosmowska, Krystyna Ossowska, Urszula Głowacka, Jadwiga Wardas

Open access · bronzeAbstract read
In one paragraph

Article in CNS neuroscience & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Is the inferior olive central to essential tremor? Yes.International review of neurobiology · 2022
    Article
  6. Review
  7. Review
  8. Adenosine receptors as promising targets for the management of ocular diseases.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2021
    Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Barbara KosmowskaDepartment of Neuro-Psychopharmacology, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.
Krystyna OssowskaDepartment of Neuro-Psychopharmacology, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.ORCID http://orcid.org/0000-0002-8381-6632
Urszula GłowackaDepartment of Neuro-Psychopharmacology, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.
Jadwiga WardasDepartment of Neuro-Psychopharmacology, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.ORCID http://orcid.org/0000-0002-0208-1946
Maj Institute of Pharmacology · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe aim of this study was to examine the role of adenosine A

methodsHarmaline was injected at a dose of 15 mg/kg ip and tremor was measured automatically in force-plate actimeters by an increased averaged power in the frequency band of 9-15 Hz (AP2) and by tremor index (a difference in power between AP2 and averaged power in the frequency band of 0-8 Hz). The zif-268 mRNA expression was additionally analyzed by in situ hybridization in several brain structures.

results5'Cl5'd-(±)-ENBA (0.05-0.5 mg/kg ip) dose dependently reduced the harmaline-induced tremor and this effect was reversed by 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), a selective antagonist of adenosine A

conclusionThis study suggests that adenosine A

Indexed as

Adenosine A1 Receptor AgonistsAnimalsBrainDeoxyadenosinesDisease Models, AnimalDose-Response Relationship, DrugDrug Evaluation, PreclinicalEarly Growth Response Protein 1HarmalineMaleMotor CortexNorbornanesRats, WistarReceptor, Adenosine A1RNA, MessengerTremor5'-chloro-5'-deoxy-N6-(norborn-2-yl)adenosineAdenosine A1 Receptor AgonistsDeoxyadenosinesEarly Growth Response Protein 1Egr1 protein, ratHarmalineNorbornanesReceptor, Adenosine A1RNA, Messengeradenosine A1 receptor agonistessential tremorharmalinetremorolytic effectzif-268

Identifiers

PMID28371468
PMCPMC6492700
OpenAlexW2601736829

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.